68Ga-PSMA-PET/CT for the evaluation of liver metastases in patients with prostate cancer
Open Access
- 11 June 2019
- journal article
- research article
- Published by Springer Nature in Cancer Imaging
- Vol. 19 (1) , 37
Abstract
The purpose of this study was to evaluate the imaging properties of hepatic metastases in 68Ga-PSMA positron emission tomography (PET) in patients with prostate cancer (PC). 68Ga-PSMA-PET/CT scans of PC patients available in our database were evaluated retrospectively for liver metastases. Metastases were identified using 68Ga-PSMA-PET, CT, MRI and follow-up scans. Different parameters including, maximum standardized uptake values (SUVmax) of the healthy liver and liver metastases were assessed by two- and three-dimensional regions of interest (2D/3D ROI). One hundred three liver metastases in 18 of 739 PC patients were identified. In total, 80 PSMA-positive (77.7%) and 23 PSMA-negative (22.3%) metastases were identified. The mean SUVmax of PSMA-positive liver metastases was significantly higher than that of the normal liver tissue in both 2D and 3D ROI (p ≤ 0.05). The mean SUVmax of PSMA-positive metastases was 9.84 ± 4.94 in 2D ROI and 10.27 ± 5.28 in 3D ROI; the mean SUVmax of PSMA-negative metastases was 3.25 ± 1.81 in 2D ROI and 3.40 ± 1.78 in 3D ROI, and significantly lower than that of the normal liver tissue (p ≤ 0.05). A significant (p ≤ 0.05) correlation between SUVmax in PSMA-positive liver metastases and both size (ρSpearman = 0.57) of metastases and PSA serum level (ρSpearman = 0.60) was found. In 68Ga-PSMA-PET, the majority of liver metastases highly overexpress PSMA and is therefore directly detectable. For the analysis of PET images, it has to be taken into account that also a significant portion of metastases can only be detected indirectly, as these metastases are PSMA-negative.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (5943/31/41/91)
This publication has 34 references indexed in Scilit:
- Clinical characteristics and prognostic factors of prostate cancer with liver metastasesTumor Biology, 2013
- PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesionsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2012
- Expression of prostate‐specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non‐polyglutamated folate, folic acidThe Prostate, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Small Cell Carcinoma of the ProstateAmerican Journal of Surgical Pathology, 2008
- Imaging of liver metastases: MRICancer Imaging, 2007
- Liver metastases in prostate carcinoma: clinical characteristics and outcomeBJU International, 2006
- Androgen-Independent Prostate Cancer Is a Heterogeneous Group of DiseasesCancer Research, 2004
- Neuroendocrine Differentiation in Hormone Refractory Prostate Cancer Following Androgen Deprivation TherapyEuropean Urology, 2004
- CT and MR Imaging of Hepatic MetastasesAmerican Journal of Roentgenology, 2000